Ascendis Pharma A/S (ASND) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings.

Is ASND or BNTX more profitable?

BioNTech has a net margin of -15.16% compared to Ascendis Pharma A/S's net margin of -130.33%. Ascendis Pharma A/S's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-130.33%	N/A	-48.77%
BioNTech	-15.16%	-2.35%	-2.05%

Do analysts prefer ASND or BNTX?

Ascendis Pharma A/S currently has a consensus price target of $191.77, suggesting a potential upside of 40.61%. BioNTech has a consensus price target of $140.76, suggesting a potential upside of 24.48%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92
BioNTech	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.82

Does the media prefer ASND or BNTX?

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 7 mentions for BioNTech. Ascendis Pharma A/S's average media sentiment score of 0.92 beat BioNTech's score of 0.66 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in ASND or BNTX?

15.5% of BioNTech shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has more volatility & risk, ASND or BNTX?

Ascendis Pharma A/S has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500.

Which has higher valuation and earnings, ASND or BNTX?

BioNTech has higher revenue and earnings than Ascendis Pharma A/S. BioNTech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$327.43M	25.26	-$521.07M	-$8.08	-16.88
BioNTech	$3.04B	8.84	$1.01B	-$2.10	-53.85

Does the MarketBeat Community favor ASND or BNTX?

Ascendis Pharma A/S received 300 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 66.52% of users gave Ascendis Pharma A/S an outperform vote while only 45.87% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 439 66.52%	Underperform Votes 221 33.48%
BioNTech	Outperform Votes 139 45.87%	Underperform Votes 164 54.13%

Summary

Ascendis Pharma A/S beats BioNTech on 11 of the 18 factors compared between the two stocks.